Objective: The aim of this study was to evaluate the efficacy and safety of Jiawei Xiaoyao San for irritable bowel syndrome. Method: We searched the VIP

CNKI

Wanfang and China biology medicine disc(CBMdisc) databases. Randomized controlled trials of clinical therapeutic studies on Jiawei Xiaoyao San for irritable bowel syndrome were included. The quality of included studies was evaluated and Meta-analysis was performed. Result: In this study

17 trials involving 1 542 patients were included. Meta-analysis indicated that Jiawei Xiaoyao San was lower in the recurrence rate and more effective than other drugs in improving symptoms and signs of irritable bowel syndrome. The RR value (95%CI)were[RR=0.33

95%CI(0.22

0.49)

P <0.000 01]and[RR=1.31

95%CI(1.24

1.38)

P< 0.000 01]

respectively. The most included researches did not report adverse reactions. Conclusion: Based on this review

Jiawei Xiaoyao San is effective for irritable bowel syndrome. However

the evidence is not strong enough due to the low quality of included trials. Further

large-sample and multi-center studies are needed.